BURNABY, British Columbia, 29 September 2017
Lungpacer Medical, Inc., announced today that the first subject has been enrolled in the RESCUE 2 European CE Mark clinical study of its proprietary phrenic-nerve pacing system. This is a randomized study being conducted in France and Germany, to evaluate the safety and effectiveness of the Lungpacer Therapy System in subjects who are expected to have Ventilator Induced Diaphragm Dysfunction and be difficult to wean from mechanical ventilation. The first subject was enrolled at the University Hospital RWTH Aachen, Germany.
